D. E. Shaw & Co., Inc. Syndax Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 352,358 shares of SNDX stock, worth $4.61 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

352,358

Holding current value

$4.61 Million

% of portfolio

0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $3.69 Million - $5.1 Million	205,715 Added 140.28%	352,358 $6.78 Million
Q2 2024 Aug 14, 2024	BUY	$18.82 - $23.79 $2.6 Million - $3.29 Million	138,119 Added 1620.35%	146,643 $3.01 Million
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $659,122 - $821,645	-33,441 Reduced 79.69%	8,524 $202,000
Q4 2023 Feb 14, 2024	SELL	$11.39 - $21.67 $1.21 Million - $2.31 Million	-106,607 Reduced 71.75%	41,965 $906,000
Q3 2023 Nov 14, 2023	SELL	$14.52 - $21.77 $354,970 - $532,211	-24,447 Reduced 14.13%	148,572 $2.16 Million
Q2 2023 Aug 14, 2023	BUY	$19.35 - $22.31 $656,971 - $757,469	33,952 Added 24.41%	173,019 $3.62 Million
Q1 2023 May 15, 2023	SELL	$20.66 - $28.98 $441,462 - $619,244	-21,368 Reduced 13.32%	139,067 $2.94 Million
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $668,880 - $850,359	32,407 Added 25.31%	160,435 $4.08 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $2.37 Million - $3.17 Million	128,028 New	128,028 $3.08 Million
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $1.83 Million - $2.73 Million	-123,303 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.23 - $22.47 $3.26 Million - $4.81 Million	-213,843 Reduced 63.43%	123,303 $2.7 Million
Q3 2021 Nov 15, 2021	SELL	$13.87 - $19.8 $1.02 Million - $1.45 Million	-73,321 Reduced 17.86%	337,146 $6.44 Million
Q2 2021 Aug 16, 2021	SELL	$13.42 - $25.18 $2.19 Million - $4.12 Million	-163,471 Reduced 28.48%	410,467 $7.05 Million
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $1.56 Million - $1.99 Million	-81,069 Reduced 12.38%	573,938 $12.8 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $6.12 Million - $10.7 Million	405,580 Added 162.6%	655,007 $14.6 Million
Q3 2020 Nov 16, 2020	BUY	$13.39 - $17.48 $1.99 Million - $2.6 Million	148,836 Added 147.96%	249,427 $3.68 Million
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $205,780 - $482,917	23,018 Added 29.67%	100,591 $1.49 Million
Q1 2020 May 15, 2020	BUY	$6.65 - $12.03 $92,036 - $166,495	13,840 Added 21.72%	77,573 $851,000
Q4 2019 Feb 14, 2020	BUY	$5.43 - $9.22 $346,070 - $587,618	63,733 New	63,733 $559,000
Q1 2018 May 15, 2018	SELL	$8.71 - $14.82 $200,878 - $341,793	-23,063 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$7.8 - $12.94 $57,977 - $96,183	7,433 Added 47.56%	23,063 $202,000
Q3 2017 Nov 14, 2017	BUY	$10.9 - $12.73 $170,367 - $198,969	15,630	15,630 $183,000

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account